iCAD

At iCAD, we believe in the possibility of creating a world where cancer can't hide. As a global medical technology leader, iCAD leverages the power of artificial intelligence (AI) to empower healthcare providers to more accurately, reliably, and quickly detect disease and improve patient outcomes. Headquartered in Nashua, New Hampshire, iCAD has been at the forefront of cancer detection technology since 1984, developing innovative solutions that transform how radiologists approach screening and diagnosis.

The company's flagship ProFound Breast Health Suite offers a comprehensive portfolio of clinically proven AI technologies for breast cancer detection, automated breast density assessment, and short-term personalized risk evaluation. These solutions provide certainty and peace of mind, optimizing every patient's opportunity to live better, longer lives. With decades of experience and a presence in over 50 countries, iCAD has read more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis exams. Now part of DeepHealth, the company continues its mission to democratize access to AI-powered mammography and advance early cancer detection globally.